Xanthine Oxidase Inhibition by Febuxostat Attenuates Experimental Atherosclerosis in Mice

Citations Over TimeTop 10% of 2014 papers

Abstract

Atherosclerosis is a chronic inflammatory disease due to lipid deposition in the arterial wall. Multiple mechanisms participate in the inflammatory process, including oxidative stress. Xanthine oxidase (XO) is a major source of reactive oxygen species (ROS) and has been linked to the pathogenesis of atherosclerosis, but the underlying mechanisms remain unclear. Here, we show enhanced XO expression in macrophages in the atherosclerotic plaque and in aortic endothelial cells in ApoE(-/-) mice, and that febuxostat, a highly potent XO inhibitor, suppressed plaque formation, reduced arterial ROS levels and improved endothelial dysfunction in ApoE(-/-) mice without affecting plasma cholesterol levels. In vitro, febuxostat inhibited cholesterol crystal-induced ROS formation and inflammatory cytokine release in murine macrophages. These results demonstrate that in the atherosclerotic plaque, XO-mediated ROS formation is pro-inflammatory and XO-inhibition by febuxostat is a potential therapy for atherosclerosis.

Related Papers

• → Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout(2018)869 cited
• → Stereochemistry of nucleic acids and their constituents. XXIX. Crystal and molecular structure of allopurinol, a potent inhibitor of xanthine oxidase(1972)52 cited
• → Allopurinol to Febuxostat: How far have we come?(2010)14 cited
• → Febuxostat Efficacy in Allopurinol-Resistant Tophaceous Gout(2011)4 cited
• Febuxostat (Uloric) for chronic treatment of gout.(2009)